Profile
Mohamad Hussein has worked as a Director at ChemioCare, Inc. and Starton Therapeutics, Inc.
Mohamad Hussein active positions
| Companies | Position | Start |
|---|---|---|
ChemioCare, Inc.
 ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | Director/Board Member | - |
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | Health Technology |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |
- Stock Market
- Insiders
- Mohamad Hussein
